Literature DB >> 7179418

A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana.

J Alexander.   

Abstract

Vaccinating CBA mice with radioattenuated Leishmania major amastigotes but not with radioattenuated L. mexicana mexicana amastigotes rendered them highly resistant to subsequent infection with L. m. mexicana. Unvaccinated CBA mice were highly susceptible to infection with L. m. mexicana producing rapidly growing non-ulcerating cutaneous lesions. Two manifestations of resistance were induced in vaccinated animals depending on the timing of the challenge infection: no lesions appeared at the site of subcutaneous challenge in animals vaccinated four or more weeks previously, while lesions grew rapidly but ulcerated and healed in animals vaccinated less than 3 weeks beforehand. L. major amastigotes were found to be markedly more resistant to gamma irradiation than L. m. mexicana amastigotes both as measured by their ability to infect susceptible strains of mice and to transform and multiply as promastigotes in NNN medium.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7179418     DOI: 10.1016/0035-9203(82)90232-2

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  13 in total

Review 1.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

2.  Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants.

Authors:  T Aebischer; M Wolfram; S I Patzer; T Ilg; M Wiese; P Overath
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

3.  Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis.

Authors:  Kevin W Bruhn; Ron Birnbaum; Jacquelyn Haskell; Veena Vanchinathan; Stephanie Greger; Rupa Narayan; Pei-Lin Chang; Thu Anh Tran; Suzanne M Hickerson; Stephen M Beverley; Mary E Wilson; Noah Craft
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

4.  Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections.

Authors:  J Alexander; P M Kaye
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

5.  Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major.

Authors:  D M Yang; M V Rogers; F Y Liew
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

6.  TNF-alpha reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis.

Authors:  F Y Liew; Y Li; D M Yang; A Severn; F E Cox
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

7.  Therapeutic immunization with radio-attenuated Leishmania parasites through i.m. route revealed protection against the experimental murine visceral leishmaniasis.

Authors:  Sanchita Datta; Madhumita Manna; Supriya Khanra; Moumita Ghosh; Radhaballav Bhar; Anindita Chakraborty; Syamal Roy
Journal:  Parasitol Res       Date:  2012-03-23       Impact factor: 2.383

Review 8.  The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates.

Authors:  Greta Volpedo; Parna Bhattacharya; Sreenivas Gannavaram; Thalia Pacheco-Fernandez; Timur Oljuskin; Ranadhir Dey; Abhay R Satoskar; Hira L Nakhasi
Journal:  Pathogens       Date:  2022-04-02

Review 9.  Live vaccination tactics: possible approaches for controlling visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahareh Taheri; Sima Rafati
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561

Review 10.  Post-Genomics and Vaccine Improvement for Leishmania.

Authors:  Negar Seyed; Tahereh Taheri; Sima Rafati
Journal:  Front Microbiol       Date:  2016-04-06       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.